Oxyntomodulin (OXM) is a peptide hormone, secreted from the gut in response to food intake, that acts as a dual agonist for both GLP-1 and glucagon receptors. It plays a role in regulating appetite, energy expenditure, and potentially glucose homeostasis. Studies suggest OXM can lead to weight loss and improved glucose tolerance in obese individuals. OXM is derived from proglucagon in intestinal L-cells. Its release is triggered by nutrient ingestion, with higher concentrations observed after meals. OXM activates both the GLP-1 receptor and the glucagon receptor. This dual action is a key area of research, as it may offer a more comprehensive approach to treating metabolic disorders compared to targeting only one receptor. Due to its effects on appetite, weight, and potentially glucose control, OXM and its analogs are being investigated as potential treatments for obesity and type 2 diabetes.
This targeted toxin recognizes cells that express the GLP-1 or glucagon receptors. The antibody in this conjugate does not cross-react with glucagon. Anti-OXM-SAP is a chemical conjugate of the antibody to oxyntomodulin and the ribosome-inactivating protein, saporin.
The following control is included for validating the specificity of the beta conjugate: Mouse IgG-SAP (Cat. #IT-18)
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.